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INTRODUCTION
In Japan, increased consumption of European/
American food and rising stress levels has elevated
the incidence of intestinal disorders (1). Along with
the growing consumer awareness of intestinal health
and enteric bacteria, some types of beneficial bacte-
ria contained in yogurts, fermented milk, and other
fermented foods have been recognized as probiotic
(2). Some non-digestible dietary fibers, such as in-
ulin or fructooligosaccharides, have been shown to
increase levels of beneficial bacteria for human
health such as bifidobacteria and lactobacilli, result-
ing in reduced intestinal pH, improved intestinal
environments, and suppressed intestinal disorders
(3, 4). Non-digestible food ingredients that benefi-
cially affect the host by selectively stimulating the
growth and/or activity of one or a limited number
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of bacterial species already resident in the colon are
defined as prebiotic (4).
Brown rice fermented by Aspergillus oryzae
(FBRA) is a processed food prepared by fermenting
brown rice and rice bran with A. oryzae. It has pre-
viously been reported that FBRA has a preventive
effect on azoxymethane-induced colon carcinogene-
sis and dextran sulfate sodium-induced acute coli-
tis in rats (5, 6). FBRA contains a large proportion
of fiber, and dietary administration of 10% FBRA to
rats increased viable cell numbers of lactobacilli in
feces (7). Beta-glucan and arabinoxylan, the main
constituents in dietary fiber in FBRA, have been
reported to stimulate growth of bifidobacteria and
lactobacilli strains in vitro (8). Moreover, FBRA has
been eaten for over 30 years in Japan by many
people, as well as consumed in clinical trials, and no
serious side effects have been reported (9, 10).
In the present study, we first examined the prebi-
otic effects of FBRA in in vitro incubation with feces.
We then conducted a placebo-controlled, double-
blinded, crossover study to examine the effects of
FBRA on the intestinal environments in human
adults. As ingestion of prebiotics and probiotics in
adults is thought to prevent a range of diseases (4,
11, 12), we investigated the effects of FBRA in
adults with no obvious illnesses, even though the
effects of prebiotics and/or probiotics have been
mostly examined in patient groups, elderly, or in-
fants. The main end points of the study were in-
creased levels of bifidobacteria and organic acids in
feces. Organic acids were produced by intestinal
bacteria in the large intestine, decrease intestinal
pH, thereby suppressing the growth of pathogenic
bacteria and increase in putrefactive metabolites,
and have growth-promoting and differentiation ac-
tivities on the colonic epithelium (13-16). In addi-
tion, organic acids have been noted to have immu-
nomodulatory effects on colonic inflammation (16,
17). The effects of FBRA on fecal microbiota, fecal
environments including pH, and putrefactive com-
ponents, and bowel function were also investigated
as sub end points.
MATERIALS AND METHODS
Chemicals, media and bacterial strains
Blood liver agar (BL), Rogosa SL agar, Trypticase
soy blood agar (TS) and desoxycholate hydrogen
sulphide lactose agar (DHL) were obtained from
Nissui Pharmaceuticals Co., Ltd. (Tokyo, Japan).
Bifidobacterium longum strain JCM1217 was ob-
tained from the Japan Collection of Microorganisms,
RIKEN Bioresource Center. Chemicals, unless oth-
erwise stated, were reagent grade or higher and ob-
tained from Sigma Chemical Co. (St. Louis, MO,
USA) or Wako Pure Chemical Industries Co., Ltd.
(Osaka, Japan).
In vitro incubation of FBRA in human fecal slurries
Fresh feces from 6 adult volunteers were sus-
pended in 9 volumes of 0.1M NaHCO3/CO2 buffer
(pH 6.8) and incubated anaerobically with 10%
FBRA for 0, 6, and 24 hr. Aliquots of each sample
were centrifuged, and the supernatants used to
measure organic acid content. Fecal DNA in the pel-
lets were extracted and used to examine changes
in microbiota by T-RFLP analysis and bifidobacteria-
specific real-time PCR.
Clinical study participants
Participants were recruited on complying with the
protocol approved by the Tokushima University
Hospital Ethics Committee on Clinical Research.
Exclusion criteria were presence of food allergy, se-
rious illness, and periodic taking of antibiotic drugs
or agents known to influence bowel condition. Af-
ter the significance and protocol of the study had
been explained, informed consent was obtained
from all participants. Thirty-six adults (14 male and
22 female, aged 22-67, Table 1) participated in the
study. This study was conducted according to the
Helsinki Declaration of 1975, as revised in 2000.
Test foods
Test foods used in this study were provided by
Genmaikoso Co., Ltd. (Sapporo, Japan). The main
components of FBRA and control food (non func-
tional food, NF) are shown in Table 2. FBRA was
made from brown rice and rice bran fermented with
A. oryzae. NF was made from roasted flour and
cornstarch (85 : 15, W/W). Both foods were granu-
lated and 3.5 g amounts packed individually.
Table 1 Profile of participants
FBRA NF age
Participant 18 18 22-67
male 8 6 22-45
female 10 12 22-67
H. Nemoto, et al. Effects of fermented brown rice on the intestinal environments236
Study Design
We conducted a placebo - controlled, double -
blinded crossover study. Subjects were instructed
not to change their normal daily activities such as
dietary and exercise habits. The study period was 16
weeks. Participants were randomly divided into
two groups by drawing lottery for group accord-
ing to written ID. Group A ingested FBRA for two
weeks prior to NF ingestion and group B ingested
vise versa . We set a 12-week intermission period be-
tween the ingestion periods to wash out the influ-
ence of the former test food. Participants took 21 g
per day of the test food (7.0 g after every meal) and
fresh feces were collected before and at the end of
each ingestion period. Feces were kept cold and
anaerobic until sent to our laboratory and processed.
In this clinical trial, administrators were Kataoka
Ph.D for enrollment, Arimochi Ph.D for allocation
and blinding, and Sei MD.Ph.D (Institute of Health
Biosciences, the University of Tokushima Graduate
School) for the data fixation and supervision of
safety and ethics.
Dietary habits and bowel-function questionnaire
Dietary habits were evaluated by using Excel-
Eiyoukun ver.4 software and Food Frequency Ques-
tionnaire Based on Food Groups ver.2 software
(FQQg, Office of Nutrition Data Base, Shikoku Uni-
versity, Tokushima, Japan). The frequency of evacu-
ation, shape, and amount of stools, as well as any
abdominal discomfort or pain were self-reported
using a bowel-function questionnaire. Participants
filled in the questionnaires before and after each
ingestion period.
Fecal microbiota analysis by culture methods
Viable cell numbers were analyzed according to
the procedure of Mitsuoka et al. (18) with slight
modification as described by Kataoka et al. (7). BL
agar and Rogosa SL agar were used to count anaero-
bic bacteria and bifidobacteria. TS agar and DHL
agar were used for counting aerobes, Enterobacte-
riaceae, and Gram-positive cocci. Results were cal-
culated as log10 of colony forming unit (CFU) per
gram (wet weight) of the initial material. Total num-
bers of fecal bacteria were counted by microscopy
after Gram stain.
Fecal microbiota analysis by Terminal-Restriction
Fragment Length Polymorphism (T-RFLP)
Fecal and bacterial DNA were isolated accord-
ing to the method of Morita et al. (19) and T-RFLP
analysis of fecal microbiota performed as described
by Sakamoto et al. (20) Briefly, 16S ribosomal DNA
from samples were amplified with PCR Thermal
Cycler Dice Standard (Takara, Otsu, Japan) and di-
gested with either HhaI or MspI (Takara). Length
of the terminal-restriction fragments (T-RFs) was
determined using an ABI Prism 310 Genetic ana-
lyzer, GeneScan Analysis Software 3.7.1 (Applied
Biosystems, Japan). GeneScanTM 1200 LIZ (Applied
Biosystems) was used as a size standard. T-RFs pat-
terns were analyzed by BioNumericsTM ver.5.01 soft-
ware (Applied Maths, Sint-Martens-Latem, Bel-
gium) to construct dendrograms. Distances between
samples were represented graphically by construct-
ing a dendrogram based on Dice coefficients of the
T-RFLP profiles. The Ward method was used for
establishing the dendrogram type. Microbiota Pro-
filer software (INFOCOM CORPORATION, Tokyo,
Japan) was used to find intestinal bacteria with T-
RFs that increased or decreased in response to
FBRA ingestion.
Real Time PCR for bifidobacteria
As bifidobacteria were difficult to detect precisely
by T-RFLP conditions used in this study (21, 22),
changes in bifidobacterial numbers in response to
test food was examined by real time PCR accord-
ing to Matsuki et al (23). SYBR Premix Ex TaqTM
II (Takara) and an ABI Prism 7000 were used ac-
cording to the manufacturers’ instructions. The am-
plification program used was : preheating at 95for
30 sec ; 40 cycles of denaturation at 95for 5 sec,
annealing at 57for 5 sec, and extension at 72
for 31 sec ; followed by a final dissociation protocol
to verify specific amplification. As a copy number
standard, pCRBL2 plasmid DNA was used at 102-
108 copies. pCRBL2 consisted of the pCR2-TOPO
vector (Invitrogen, Tokyo, Japan) that harbored 16S
Table 2 Composition of test food
FBRA NF
/100 g /21 g /100 g /21 g
Energy (kcal) 421.0 88.4 376.0 79.0
Protein (g) 16.3 3.42 8.2 1.72
Lipid (g) 24.7 5.19 1.0 0.21
Glycol (g) 21.3 4.47 82.6 17.35
Dietary fiber (g) 24.1 5.06 2.2 0.42
soluble fiber (g) 3.8 0.80 1.1 0.23
insoluble fiber (g) 20.4 4.28 1.0 0.21
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ribosomal DNA of B. longum strain JCM 1217. The
genetic recombination experiments performed in
this study were approved by the University of
Tokushima.
Measurement of fecal concentration of organic acid
Portions (about 0.2 g each) of homogenized stool
were suspended in 1 ml water and centrifuged at
4at 10 krpm for 10 min. Supernatants were stored
at -80until gas chromatograph analysis.
Organic acid concentrations in the fecal extracts
were measured using a gas chromatograph instru-
ment (GC -7AG, Shimadzu, Kyoto, Japan) and a
GLC glass column (3 mm2 m) packed with 10%
Reoplex 400 on Chromosorb W (80 -100 mesh,
AW). The column temperature was 130and the
temperature of the injection port and flame ioniza-
tion detector was 210. Nitrogen was used as the
carrier gas at a flow rate of 50 ml/min. Mixtures of
volatile fatty acids (VFAs) (acetic acid, propionic
acid, isobutyric acid, butyric acid, isovaleric acid,
valeric acid, isocapuronic acid, capuronic acid, 10
mM each) and non-volatile fatty acids (NVFAs)
(lactic acid, succinic acid, 10 mM each) were used
as external standards. Fecal extract (0.5 ml) and
standard VFAs (0.5 ml) were acidified with 5 μl 50%
sulfuric acid, extracted with an equal volume of di-
ethylether, and 1 μl of the ether layer injected into
the gas chromatograph. VFAs in the fecal extracts
were removed by two more extractions with dieth-
ylether. The remaining water layer (100 μl) and
NVFA standard solution (100 μl) were esterified by
heating at 100for 5 min in the presence of an
equal volume of boron trifluoride methanol com-
plex (Nacalai Tesque, Inc., Kyoto, Japan). NVFA
methylesters were extracted with 100 μl chloroform
and injected into the gas chromatograph.
Fecal pH and water content
Stool samples (0.10.2 g) were homogenized in
1 ml of water. Fecal pH was measured with a pH
meter (Sartorius B021610 007). Water content of
feces was calculated as the weight difference be-
fore and after freeze-drying a portion of the feces
(EYELA FDU-1000).
Measurement of fecal putrefactive metabolites
Fecal levels of indole were measured as described
by Shioiri et al. (24) Briefly, stools (approximately
0.1 g) were homogenized with 9 volumes of 0.1 mM
Phosphate buffer (PB) and centrifuged. The super-
natant was appropriately diluted with PB. 0.2 ml of
diluted sample was mixed with 1 ml of coloring so-
lution (p -dimethyl aminobenzaldehyde in a sulfuric
acid/alcohol mixture) and kept at room temperature
for 20 min. The absorbance at 570 nm was meas-
ured using UV-VIS spectrophotometer (Shimadzu
UV-1200). As a control, 0 to 0.3 mM indole solution
was prepared just before use. Ammonia concentra-
tion was measured using Ammonia Test Wako
(Wako Pure Chemical Industries Co. Ltd., Osaka,
Japan).
Statistical analysis
Mann-Whitney U test and repeated measure
ANOVA using Microsoft Excel 2007 and Statcel2
add-in software (OMS publishing, Tokorozawa,
Japan) was used for the statistical analysis. A prob-
ability of less than 0.05 was taken to indicate statis-
tical significance.
RESULTS
Organic acid production in human fecal slurries
with FBRA
In vitro experiments were performed using fresh
feces from 6 healthy adults. Acetate was commonly
produced as the major metabolite, and lactate was
also a major metabolite except for slurry C (Fig. 1).
Although the pattern of accumulated organic acids
was different for each sample, substantial amounts
of propionate, butyrate, and succinate were detected
in most samples. Concentrations of total organic
acids were increased to about 300 μmol/g slurry by
incubation of feces with FBRA (Fig. 1). Incubation
of FBRA alone or fecal slurries alone resulted in no
increase of organic acids (data not shown).
Microbiota alteration in human fecal slurries with
FBRA
T-RFLP analysis of fecal slurries showed that the
initial microbiota patterns were different between
the slurries, and continued to vary following incuba-
tion with FBRA (Fig. 2). In fecal slurry A (Fig. 2A),
Bacteroides and clostridia were dominant, with the
percentages of Bacteroides and Clostridium subclus-
ter XIVa increasing after FBRA incubation. In fecal
slurry B (Fig. 2B), in which lactobacilli was the
main species, addition of FBRA increased the per-
centage of lactobacilli further (Fig. 2B). Although
the area of the 352-357 bp peak in Fig. 2B also in-
creased, a matching species except uncultured bac-
teria could not be found using the Microbiota
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Fig. 2 T-RFLP analysis of microbiota in fecal slurries before and after incubation with FBRA.
Fecal slurries prepared from 6 adults were anaerobically incubated with 10% FBRA and aliquots removed at 0 and 24 h for T-RFLP
analysis, as described in Materials and Methods. Representative T-RFLP patterns after HhaI digestion in 3 fecal slurries are shown.
These data correspond to panels A, B, and C in Fig. 1, respectively. The peak area at 95-98 bp was mainly derived from Bacteroides ;
that at 185-190 bp was ruminococci and clostridia ; that at 253-256 bp was lactobacilli ; and that at 1070-1080 bp was Clostridium sub-
cluster XIVa. The peak area at 352-357, 620-623, and 697-698 bp were deu to uncultured bacteria. These species described above
were designated using Microbiota Profiler and the combined data of HhaI and MspI digestion.
Fig. 1 Production of organic acids after in vitro incubation of fecal slurries with FBRA.
Fecal slurries from 6 adults were anaerobically incubated with 10% FBRA and aliquots removed at 0, 6, 24 h to determine the con-
centrations of organic acids (panel A-F). Organic acid concentrations were measured using a gas chromatograph instrument. VFAs
and NVFAs were used as external standards as described in Materials and Methods. A, acetate ; P, propionate ; B, butyrate ; L,
lactate ; S, succinate.
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Profiler. Increased bifidobacterial numbers following
in vitro incubation with FBRA was confirmed by real
time PCR as shown in Fig. 3. Bifidobacteria in-
creased in 4 out of 6 fecal slurries (B, D, E, and F
in Fig. 3). In fecal slurry C, Bacteroides was in-
creased and remained most dominant during incu-
bation with FBRA (Fig. 2C). Levels of bifidobacteria
in sample C were below the detection limit (100
copies/10 pg fecal DNA) before and after incuba-
tion.
Participant flow, recruitment, and adverse events
Participant flow is shown in Fig. 4. The recruit-
ment period was from 28th Oct. 2005 to 14th Apr.
2006 and the intervention period was from 7th Nov.
2005 to 16th Oct. 2006. Participants were randomly
divided into two groups and took test diets as de-
scribed in Materials and Methods. The male to fe-
male ratio and age composition were similar be-
tween the two groups. All participants completed
the trial without reporting any adverse events. One
male participant in group A was excluded from sta-
tistical analysis because he consumed antibiotics for
3 days during the first ingestion period.
Dietary habits, test food consumption, and bowel-
function questionnaires
Three participants (two in Group A and one in
Group B) were excluded from dietary habits analy-
sis because of inadequate response of question-
naires. Survey of dietary habits revealed no differ-
ences in dietary fiber intakes between Groups A and
B (Table. 3). Intake of the test foods was checked
by self-reports and the number of returned test food
portions. All subjects consumed the intended doses
of test food, although some missed doses were
taken within a day or as an added intervention day
with 21.0 g as the maximum daily dose. Samples
obtained in the first ingestion period only were used
for statistical analysis, because ingestion reports,
questionnaires about bowel condition, and question-
naires to check blinding were not collected from all
subjects after the latter period. Also, it appeared
that the bowel conditions at the start of the second
ingestion period were inconsistent with those of
the first ingestion period in some subjects. For the
bowel-function questionnaires, no significant differ-
ences in frequency of evacuation, fecal amount,
shape, and water content of feces before and after
test diet ingestion were observed for both Groups
A and B.
Fig. 4 Clinical study design and participant flow.
Participants were randomly divided into 2 groups. Intervention
was for 16 weeks : first ingestion (2 weeks), intermission (12
weeks), and second ingestion (2 weeks). The intervention was
completed with no adverse events. One subject in group A was
excluded from analysis because of antibiotic intake during the
intervention period. As questionnaires at the end of second in-
gestion were not collected from all participants, analyses were
performed on first ingestion period data only.
Fig. 3 The increasing ratio of bifidobacteria after in vitro incu-
bation of fecal slurries with FBRA.
Fecal slurries from 6 adults were incubated with 10% FBRA and
aliquots removed at 0 and 24 h to quantify bifidobacteria by real
time PCR. A copy number standard pCRBL2, harboring the 16S
ribosomal DNA of B. longum strain JCM 1217, was used to cal-
culate the copy number of the bifidobacterial 16S ribosomal RNA
gene. Values from one subject, corresponding to panel C in Fig. 1
and Fig. 2, are not shown as they fell below the detection limit
(100 copies/10 pg fecal DNA).
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Effect of FBRA ingestion on the fecal concentration
of bacterial metabolites
The concentrations of total and individual organic
acids did not significantly increase after FBRA inges-
tion and were not significantly different between
Groups A and B, as shown in Table 4. Fecal pH was
not significantly altered. Concentration of ammonia
and indole in feces were not affected significantly
between each group.
Analysis of fecal bacteria by culture and Real time
PCR methods
Total numbers of fecal bacteria counted by mi-
croscopy after Gram-staining was not significantly
different between Groups A and B, nor between be-
fore and after experimental diets (Table 5). Viable
cell numbers of bifidobacteria and Enterobacteriaceae
in feces were not significantly altered following test
diet ingestion in both Groups A and B. Real time
Table 3 Daily intake of dietary fiber before intervention
Group A (n=15/17) Group B (n=17/18)
p-value
median IQR median IQR
Total fiber (g) 10.8 9.1 - 14.3 12.2 8.0 - 14.0 0.955
Soluble fiber (g) 2.6 2.2 - 3.3 2.6 1.7 - 3.5 0.895
Insoluble fiber (g) 7.4 6.0 - 10.1 8.5 5.6 - 9.5 0.777
Total fiber amount was summed up of soluble and insoluble fiber amount. IQR : Interquartile range. Mann-Whitney U-test was used.
Table 5 Analysis of fecal bacteria in subjects before and after first ingestion period
Group A (FBRA) Group B (NF)
p ValueBefore After Before After
median IQR median IQR median IQR median IQR
Total bacteria 11.40 11.20 - 11.63 11.50 11.28 - 11.60 11.55 11.30 - 11.78 11.55 11.40 - 11.60 0.530
Culture methods
Bifidobacteria 9.60 9.35 - 9.95 9.60 9.20 - 9.95 9.75 9.50 - 10.03 9.65 9.23 - 10.00 0.216
Enterobacteriaceae 7.40 6.50 - 7.90 6.90 5.20 - 8.10 7.40 6.15 - 7.60 7.10 6.73 - 7.75 0.663
aerobic G(+)C 6.70 5.60 - 7.30 7.00 6.53 - 7.53 6.65 6.33 - 8.08 7.30 6.48 - 7.98 0.350
Total bacteriawere counted undera microscope after Gram-staining.Valuesare log10CFU/gfeces in culture method. Valuesless than-
detection limit are not included. Repeated measure ANOVA was used to compare between each group. IQR, Interquartile range ;
G(+)C, gram positive cocci.
Table 4 Concentration of metabolites and pH in feces before and after first ingestion of test diet
Group A (FBRA) Group B (NF)
p ValueBefore After Before After
median IQR median IQR median IQR median IQR
Fecal pH 7.21 6.74 - 7.51 7.13 6.69 - 7.20 6.87 6.48 - 7.18 7.22 6.49 - 7.61 0.631
Total organic acid 86.97 71.73 - 102.73 85.75 80.48 - 96.41 100.04 82.58 - 107.87 90.74 81.94 - 107.27 0.460
Acetate 40.31 32.89 - 47.66 41.71 38.25 - 48.61 50.04 35.24 - 54.17 42.55 35.52 - 50.35 0.893
Propionate 10.98 6.95 - 17.71 11.66 9.30 - 13.98 15.47 11.95 - 18.99 15.61 12.56 - 18.91 0.138
Butyrate 6.81 4.32 - 9.62 8.71 5.93 - 10.57 9.92 7.66 - 11.85 9.41 7.54 - 11.55 0.200
Lactate 19.46 17.80 - 21.05 20.59 17.83 - 22.22 19.86 17.40 - 20.95 18.34 15.69 - 22.28 0.793
Ammonia 475 283 - 641 394 199 - 644 412 276 - 463 345 301 - 529 0.569
Indole 1.04 0.33 - 1.34 0.99 0.54 - 1.67 0.78 0.60 - 0.89 1.37 0.95 - 1.87 0.542
Total organic acid concentration was summed up of each measured concentration including isobutyrate, isovalerate valerate, isocapuro-
nate, and capuronate and succinic acid. Values are μmol/g feces (wet weight) in organic acid and indole, μg/g feces (wet weight) in
ammonia. IQR : Interquartile range. Values less than detection limit are not included. Repeated measure ANOVA was used to compare
between each group.
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PCR for bifidobacteria also showed no significant
changes in response to the test diets (data not
shown).
T-RFLP analysis of human fecal microbiota before
and after FBRA ingestion
Effect of FBRA on fecal microbiota was examined
by T-RFLP analysis, which focused on the 16S ribo-
somal DNA. T-RF patterns derived from fecal bac-
teria before and after FBRA ingestion were quite
similar (70% of similarity index, Fig. 5) in most
subjects. In several subjects (12F, 22F, 24F, 25F in
Group A, 19N, 31N in Group B, Bold face in Fig. 5),
fecal microbiota was comparably altered between
before and after ingestion of test foods (50 % of
similarity, Fig. 5).
DISCUSSION
Some non-digestible dietary fibers have been re-
ported to improve functional constipation by increas-
ing bulk and gas production in the colon (25). They
allowed intestinal bifidobacteria and lactobacilli lev-
els to increase, and production of organic acids to
enhance including butyrate in the large intestine,
leading to decreased intestinal pH that suppresses
the overgrowth of pathogenic bacteria and the pro-
duction of putrefactive components such as indole
(26). Organic acids produced by gut-resident bac-
teria have beneficial aspects for host, including im-
munomodulatory effects on colonic inflammation
(13-16). In addition, butyrate is the major energy
source for colonic epithelial cells, and promotes
the proliferation and differentiation of colonic cells
and inhibits the growth of colonic cancer (16). As
FBRA contains a substantial amount of non-digest-
ible dietary fiber, we thought that FBRA could im-
prove the intestinal environment and bowel move-
ment.
The in vitro fecal slurry incubation with FBRA
showed increased organic acid production and en-
hanced bifidobacteria, which indicated that FBRA
had a potential as a prebiotic. Though the concen-
tration of total organic acid was increased in all sam-
ples, the production patterns of organic acids by
fecal bacteria differed between individuals (Fig. 1).
Coincident with the difference of organic acid pro-
ductions, T-RFLP analysis showed that fecal micro-
biota also varied markedly between subjects after
incubation with FBRA (Fig. 2), in agreement with
previous reports that the effects of prebiotics may
depend on the initial condition of the intestinal en-
vironments (27). Acetate and lactate were abundant
after incubation in fecal slurry B (Fig. 1B), in which
bifidobacteria and lactobacilli were dominant. Ace-
tate, lactate and substantial amounts of butyrate
were produced in fecal slurry A (Fig. 1A), in which
FBRA increased Bacteroides and Clostridium sub-
cluster XIVa. Succinate was abundant in fecal slurry
C (Fig. 1C), in which Bacteroides was increased af-
ter addition of FBRA but bifidobacteria were ex-
tremely low. Intestinal bacteria competitively me-
tabolize carbohydrate to various organic acids via
phosphoenolpyruvate and pyruvate. Bacteroides can
produce succinate from phosphoenolpyruvate and
pyruvate, while bifidobacteria produce lactate from
pyruvate (28). Therefore, FBRA could be metabo-
lized to organic acids in vitro , and the amount and
variety of produced organic acids was influenced by
Fig. 5 Cluster analysis of fecal microbiota of subjects before
and after first ingestion period.
The dendrogram is based on the T-RFLP patterns derived from
HhaI and MspI digests. The scale bar represents similarity in-
dices (%). Fecal microbiota of most subjects were not largely
changed after intervention. In several subjects (12F, 22F, 24F,
25F in Group A, 19N, 31N in Group B, in bold), T-RFLP patterns
after ingestion were comparably different from those before in-
gestion. F, FBRA ingestion group ; N, Non functional food inges-
tion group.
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the unique composition of the resident microbiota
in each individual.
Bifidobacteria were increased in 4 out of 6 sam-
ples after incubation of fecal slurries with FBRA for
24 h. Rice bran is rich in non-digestible dietary fi-
bers such as beta-glucan and arabinoxylan, and
these components are known to be hydrolyzed by
A. oryzae -mediated fermentation (29). Hydrolysates
of these fibers have been reported to be selective
substrates for lactobacilli and bifidobacteria (8).
Therefore, oligosaccharides produced by A. oryzae
may contribute to the increased levels of bifidobac-
teria.
The clinical study was completed without any ad-
verse events, and provided an evidence of safety of
FBRA. However, despite the positive findings from
the in vitro study, the clinical study failed to iden-
tify the effects of FBRA on organic acids and bifido-
bacteria in feces as main end points. Bifidobacteria
after FBRA ingestion remained at the same levels
as before ingestion. Other bacteria investigated in
this study were also unchanged by FBRA ingestion.
Likewise, clustering analysis derived from T-RFLP
data showed that the fecal microbiota was not af-
fected by FBRA ingestion for 2 weeks (Fig. 5). It
has been reported that Japanese adults consume
around 14 g of dietary fiber per day (30), while the
Ministry of Health, Labour and Welfare, Japan, rec-
ommends the intake of 21.0 g dietary fiber per day
(31). The United States Department of Agriculture
recommend the intake of even more dietary fiber
at around 14 g per 1000 kcal, depending on age,
gender and energy intake (32). Therefore, we set
the FBRA dosage to make up for the shortfall be-
tween actual and recommended dietary fiber in-
take. However, even allowing for the difference of
calculating method of dietary fiber, the amount of
total dietary fiber did not reach the recommended
value (21 g of fiber per day) even in FBRA inges-
tion group, as the participants had unexpectedly low
base intakes of dietary fiber (mean 11.5 g/day). In
our previous study (7), we confirmed the prebiotic
effects of FBRA in a rat model in which rats ate 1.5
g/day FBRA, which corresponds to 692 g/day in
humans on a body weight basis. Therefore, supple-
mentation of dietary fiber with FBRA at the dose
used in this study might have been insufficient to
modify intestinal microbiota. Further clinical study
for adequate ingestion dose for human adults will
be necessary.
Reflecting no modifications of fecal microbiota by
2 week ingestion of FBRA (Fig. 5), concentrations
of organic acids were also unchanged in the clinical
study (Table 4). Even though FBRA could increase
total organic acid concentrations in fecal slurries in
vitro , values were not significantly increased in vivo .
This result suggested that although FBRA was prob-
ably metabolized to organic acids by intestinal bacte-
ria in the human colon, the increased organic acids
may have been quickly removed due to their high
absorbability in the colon (28). Given the variability
in organic acid production patterns observed in in
vitro experiment and the organic acid absorption
in colon, it might be difficult to detect the prebiotic
effects from the fecal concentration of organic ac-
ids as intestinal environment indicators. Kanauchi
et al. reported that concentration of fecal butyrate
was increased by 4-weeks intake of 30 g per day of
germinated barley foodstuff (about 10 g of dietary
fiber), while Costabile et al. showed that 3-weeks
intake of 10 g per day of inulin had no effect on fe-
cal organic acids (33, 34). Considering these re-
ports, the dose of FBRA (21 g, about 5 g per day of
dietary fiber) might not be enough to affect on fe-
cal organic acid.
Bowel function and concentrations of ammonia
and indole were investigated as sub end points. As
FBRA contains substantial amounts of insoluble die-
tary fiber, we expected FBRA to stimulate bowel
peristalsis by increasing the volume of the intesti-
nal contents (26). However, FBRA intake did not
significantly affect bowel evacuation quantitatively
or qualitatively even in participants with constipation,
even though some subjects received around 1.5
times as much dietary fiber as their ordinary diets
for 2 weeks. It may be necessary to consume more
dietary fiber and/or much longer period to improve
constipation. The concentrations of ammonia and
indole were also not affected by the test diets. It had
been reported that fecal putrefactive components
can vary widely in response to daily foods on an
intra-individual and inter-individual basis (35).
Therefore, the effects of the test foods might have
been obscured by the natural variability in ammonia
and indole concentrations.
In conclusion, FBRA increased the production of
organic acids and bifidobacteria in vitro , which sup-
ported the use of FBRA as a prebiotic. Clinical study
showed the evidence of safety of FBRA. However,
as it remains unclear whether FBRA has prebiotic
effects on the intestinal environment, further clini-
cal studies for adequate ingestion dose and period
of FBRA are necessary.
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